Tris Pharma Takes Bold Step into Digital Health with AI-Driven ADHD Diagnostic Tool

Tris Pharma launches Tris Digital Health, partnering with Braingaze to commercialize an AI-enhanced, digital biomarker-based attention deficit hyperactivity disorder (ADHD) diagnostic tool in the US and Canada. This innovative technology, validated in Europe, aims to improve the accuracy of ADHD diagnoses by using eye-tracking technology within a computerized game, providing a significant improvement over the traditionally used subjective diagnostic tools.

This innovative approach offers a quantifiable method to determine ADHD probability and severity in patients, thereby providing a significant improvement over the subjective diagnostic tools traditionally used.

Ketan Mehta, founder and CEO of Tris Pharma, emphasized the urgency for better diagnostic tools. "Patients, caregivers, and physicians deserve superior tools for accurate ADHD diagnosis beyond the current methods. We have launched Tris Digital Health to deliver on our long-term commitment to advance meaningful and beneficial healthcare for physicians, ADHD patients and caregivers," Mehta stated.

The licensing agreement with Braingaze allows Tris exclusive rights to further develop and market Braingaze’s technology in North America. As part of the commercialization process, Tris Pharma will undertake clinical trials in the US to validate the efficacy and reliability of the technology, ensuring it meets the rigorous standards set by the US Food and Drug Administration (FDA).

The positive feedback from European medical professionals 

Laszlo Bax, CEO and co-founder of Braingaze, shared that European physicians have praised the diagnostic test as a significant advancement over existing methods. "We are thrilled to partner with Tris, another leader in the ADHD space who has an exceptional track record with four commercialized medications, to extend the reach of our ADHD diagnostic solutions to patients who might benefit from it in the US and Canada," said Bax.